1. Home
  2. ACRS
  3. ACRS News

Latest Aclaris Therapeutics Inc. (ACRS) News on November 27, 2025

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
ACRS

GlobeNewswire

2 days ago

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Discovering Aclaris Therapeutics And Two Other Noteworthy Penny Stocks
ACRS

Simply Wall St.

7 days ago

Discovering Aclaris Therapeutics And Two Other Noteworthy Penny Stocks

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
ACRS

Zacks

21 days ago

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates

ACRS

Associated Press Finance

21 days ago

Aclaris: Q3 Earnings Snapshot

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
ACRS

GlobeNewswire

21 days ago

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates
ACRS

Zacks

22 days ago

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates

Aclaris Therapeutics (NASDAQ:ACRS) adds US$40m to market cap in the past 7 days, though investors from three years ago are still down 83%
ACRS

Simply Wall St.

25 days ago

Aclaris Therapeutics (NASDAQ:ACRS) adds US$40m to market cap in the past 7 days, though investors from three years ago are still down 83%

What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now?
ACRS

Zacks

a month ago

What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now?

Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
ACRS

Simply Wall St.

a month ago

Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases
ACRS

Insider Monkey

4 months ago

Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
ACRS

GlobeNewswire

5 months ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
ACRS

GlobeNewswire

5 months ago

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
ACRS

GlobeNewswire

6 months ago

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Aclaris Therapeutics to Participate in Two June Healthcare Conferences
ACRS

GlobeNewswire

6 months ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

ACRS

MT Newswires

6 months ago

Wedbush Initiates Aclaris Therapeutics at Outperform With $8 Price Target

Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
ACRS

Simply Wall St.

7 months ago

Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
ACRS

GlobeNewswire

7 months ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
ACRS

Zacks

7 months ago

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

ACRS

Associated Press Finance

7 months ago

Aclaris: Q1 Earnings Snapshot

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
ACRS

GlobeNewswire

7 months ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

ACRS

MT Newswires

7 months ago

Aclaris Therapeutics Names Jesse Hall Chief Medical Officer

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
ACRS

GlobeNewswire

7 months ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Strong week for Aclaris Therapeutics (NASDAQ:ACRS) shareholders doesn't alleviate pain of three-year loss
ACRS

Simply Wall St.

7 months ago

Strong week for Aclaris Therapeutics (NASDAQ:ACRS) shareholders doesn't alleviate pain of three-year loss

Aclaris Therapeutics receives FDA approval for Phase Ia/Ib trial of ATI-052
ACRS

Clinical Trials Arena

7 months ago

Aclaris Therapeutics receives FDA approval for Phase Ia/Ib trial of ATI-052

ACRS

MT Newswires

7 months ago

Aclaris Gets FDA Clearance for Clinical Trial of Immuno-Inflammatory Treatment

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
ACRS

GlobeNewswire

7 months ago

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely?
ACRS

Simply Wall St.

8 months ago

Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely?

Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald
ACRS

TipRanks

8 months ago

Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald

Aclaris Therapeutics to Participate in Two March Healthcare Conferences
ACRS

GlobeNewswire

9 months ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year
ACRS

Simply Wall St.

9 months ago

This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year

Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
ACRS

Simply Wall St.

9 months ago

Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
ACRS

Zacks

9 months ago

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

ACRS

Associated Press Finance

9 months ago

Aclaris: Q4 Earnings Snapshot

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
ACRS

GlobeNewswire

9 months ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
ACRS

GlobeNewswire

9 months ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
ACRS

GlobeNewswire

10 months ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ACRS

MT Newswires

a year ago

HC Wainwright Upgrades Aclaris Therapeutics to Buy From Neutral, $20 Price Target

ACRS

MT Newswires

a year ago

Aclaris Therapeutics Files Statement for Share Resale by Stockholders; Stock Rises After Hours

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics And 2 Other US Penny Stocks To Watch
ACRS

Simply Wall St.

a year ago

Aclaris Therapeutics And 2 Other US Penny Stocks To Watch

ACRS

MT Newswires

a year ago

Cantor Fitzgerald Upgrades Aclaris Therapeutics to Overweight

Aclaris Therapeutics upgraded to Buy from Hold at Jefferies
ACRS

TipRanks

a year ago

Aclaris Therapeutics upgraded to Buy from Hold at Jefferies

Aclaris Therapeutics upgraded to Buy from Neutral at BTIG
ACRS

TipRanks

a year ago

Aclaris Therapeutics upgraded to Buy from Neutral at BTIG

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
ACRS

Benzinga

a year ago

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

ACRS

MT Newswires

a year ago

Aclaris Therapeutics Shares Soar After Multiple Analyst Upgrades

ACRS

MT Newswires

a year ago

Top Midday Gainers

Aclaris Therapeutics secures global rights to Biosion’s antibodies
ACRS

Pharmaceutical Technology

a year ago

Aclaris Therapeutics secures global rights to Biosion’s antibodies

ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
ACRS

Zacks

a year ago

ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs

ACRS

MT Newswires

a year ago

Piper Sandler Upgrades Aclaris Therapeutics to Overweight, Price Target is $13

ACRS

MT Newswires

a year ago

BTIG Upgrades Aclaris Therapeutics to Buy, Price Target is $8

ACRS

MT Newswires

a year ago

Jefferies Upgrades Aclaris Therapeutics to Buy, Price Target is $7

ACRS

MT Newswires

a year ago

Aclaris Therapeutics Signs License Agreement with Chinese Biotech Biosion

ACRS

MT Newswires

a year ago

Aclaris Therapeutics Raises $80 Million Through Private Placement

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
ACRS

PR Newswire

a year ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Aclaris Therapeutics Announces $80 Million Private Placement
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts
ACRS

Simply Wall St.

a year ago

News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
ACRS

Simply Wall St.

a year ago

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates
ACRS

Zacks

a year ago

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates

ACRS

Associated Press Finance

a year ago

Aclaris: Q3 Earnings Snapshot

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap
ACRS

Simply Wall St.

a year ago

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap

Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc
ACRS

GuruFocus.com

a year ago

Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc

Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?
ACRS

Zacks

a year ago

Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?

Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial
ACRS

Clinical Trials Arena

a year ago

Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
ACRS

Simply Wall St.

a year ago

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aclaris Therapeutics Second Quarter 2024 Earnings: Beats Expectations
ACRS

Simply Wall St.

a year ago

Aclaris Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
ACRS

Zacks

a year ago

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

ACRS

Associated Press Finance

a year ago

Aclaris: Q2 Earnings Snapshot

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely?
ACRS

Simply Wall St.

a year ago

Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely?

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
ACRS

Zacks

a year ago

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

ACRS

MT Newswires

a year ago

Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
ACRS

Zacks

a year ago

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

ACRS

MT Newswires

a year ago

Aclaris Therapeutics Insider Bought Shares Worth $405,894, According to a Recent SEC Filing

ACRS

MT Newswires

a year ago

Aclaris Therapeutics Insider Bought Shares Worth $1,742,075, According to a Recent SEC Filing

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates
ACRS

Simply Wall St.

2 years ago

Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
ACRS

Insider Monkey

2 years ago

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript

ACRS

Thomson Reuters StreetEvents

2 years ago

Q1 2024 Aclaris Therapeutics Inc Earnings Call

ACRS

GuruFocus.com

2 years ago

Aclaris Therapeutics Inc (ACRS) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
ACRS

Zacks

2 years ago

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates

ACRS

Associated Press Finance

2 years ago

Aclaris: Q1 Earnings Snapshot

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
ACRS

GlobeNewswire

2 years ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
ACRS

GlobeNewswire

2 years ago

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
ACRS

PR Newswire

2 years ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock
ACRS

Simply Wall St.

2 years ago

Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
ACRS

Zacks

2 years ago

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
ACRS

Zacks

2 years ago

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

Aclaris (ACRS) Upgraded to Buy: Here's Why
ACRS

Zacks

2 years ago

Aclaris (ACRS) Upgraded to Buy: Here's Why

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
ACRS

Zacks

2 years ago

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

Aclaris Therapeutics Full Year 2023 Earnings: Beats Expectations
ACRS

Simply Wall St.

2 years ago

Aclaris Therapeutics Full Year 2023 Earnings: Beats Expectations

Analysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51%
ACRS

Simply Wall St.

2 years ago

Analysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51%

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
ACRS

Zacks

2 years ago

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

ACRS

Associated Press Finance

2 years ago

Aclaris: Q4 Earnings Snapshot

Share on Social Networks: